Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8454129 | Lung Cancer | 2018 | 9 Pages |
Abstract
Surgery for cT1-2, N0-1, M1 or cT3, N0, M1 disease is associated with a 5-year survival of 25% and does not appear to compromise outcomes when compared to non-operative therapy, supporting guidelines that recommend surgery for very select patients with stage IV disease. However, surgery provides less benefit and should be considered much less often for stage IV patients with mediastinal nodal disease or more locally advanced tumors.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Chi-Fu Jeffrey Yang, Lin Gu, Shivani A. Shah, Babatunde A. Yerokun, Thomas A. D'Amico, Matthew G. Hartwig, Mark F. Berry,